NeuroScientific Biopharmaceuticals Investor Relations Material
Latest events
Investor Presentation
18 Aug, 2025
Q4 2025
22 Jul, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NeuroScientific Biopharmaceuticals Limited
Access all reports
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on researching and developing therapies for neurodegenerative diseases and neurotrauma. The company’s work centers on novel peptide-based treatments aimed at conditions such as Alzheimer’s disease, multiple sclerosis, and other neurological disorders that involve degeneration or damage to nerve cells. The company is headquartered in Perth, Australia, and its shares are listed on the ASX.
Key slides for NeuroScientific Biopharmaceuticals Limited
Investor Presentation
NeuroScientific Biopharmaceuticals Limited
M&A Announcement
NeuroScientific Biopharmaceuticals Limited
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
NSB
Country
🇦🇺 Australia